Pune, 8th August 2026: The Food and Drug Administration (FDA) has permanently cancelled the Ayurvedic drug manufacturing licence of Inducare Pharma Pvt. Ltd., located in the Maharashtra Industrial Development Corporation (MIDC) area of Jejuri in Pune district, after serious quality violations were found in six of its Ayurvedic medicines.
The FDA found fungal growth, excessive microbial levels, black spots on tablets, insects, larvae and other foreign impurities in samples of the medicines. The affected products were declared substandard.
The medicines found to be defective include:
Sinhanad Guggul
Punarnavadi Mandoor
Triphala Guggul
Kanchanar Guggul
Hingvashtak Churna
Triphala Churna
FDA officials found fungal growth in some samples, while microbial contamination exceeded prescribed limits. In some powdered medicines, insects, larvae and other foreign substances were also detected.
During two inspections of the company, the FDA found several violations of the Drugs and Cosmetics Act and applicable manufacturing rules. These included:
Lack of proper records proving the manufacturing process
Incomplete batch manufacturing records
Failure to conduct quality tests on raw materials
Inadequate laboratory facilities
Poor cleanliness in the production area
Lack of proper machinery records
No adequate system for controlling temperature and humidity
Absence of proper records of medicine sales
Following the findings, the FDA ordered the company to immediately stop manufacturing the medicines and issued a show-cause notice. The company was given an opportunity to submit a written explanation and appear for a personal hearing.
However, the company failed to provide a satisfactory explanation or sufficient evidence showing compliance with the required manufacturing standards. After considering the inspection findings and other documents, the licensing authority ordered the permanent cancellation of Inducare Pharma's Ayurvedic drug manufacturing licence.
